JP2013508344A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508344A5 JP2013508344A5 JP2012534763A JP2012534763A JP2013508344A5 JP 2013508344 A5 JP2013508344 A5 JP 2013508344A5 JP 2012534763 A JP2012534763 A JP 2012534763A JP 2012534763 A JP2012534763 A JP 2012534763A JP 2013508344 A5 JP2013508344 A5 JP 2013508344A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- metal ion
- salt
- composition according
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 34
- 229910021645 metal ion Inorganic materials 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 239000013543 active substance Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 8
- 239000000843 powder Substances 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 4
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims 3
- 229960002401 calcium lactate Drugs 0.000 claims 3
- 239000001527 calcium lactate Substances 0.000 claims 3
- 235000011086 calcium lactate Nutrition 0.000 claims 3
- 229920005862 polyol Polymers 0.000 claims 3
- 150000003077 polyols Chemical class 0.000 claims 3
- 230000000975 bioactive effect Effects 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 229940124748 beta 2 agonist Drugs 0.000 claims 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims 1
- 239000001354 calcium citrate Substances 0.000 claims 1
- PWKNEBQRTUXXLT-ZBHRUSISSA-L calcium lactate gluconate Chemical compound [Ca+2].CC(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O PWKNEBQRTUXXLT-ZBHRUSISSA-L 0.000 claims 1
- 229940041131 calcium lactate gluconate Drugs 0.000 claims 1
- HPVJXNNKHRNBOY-UHFFFAOYSA-L calcium;2-hydroxypropanoate;pentahydrate Chemical compound O.O.O.O.O.[Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O HPVJXNNKHRNBOY-UHFFFAOYSA-L 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 150000004683 dihydrates Chemical class 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims 1
- 229960001008 heparin sodium Drugs 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 239000006104 solid solution Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960000257 tiotropium bromide Drugs 0.000 claims 1
- 235000013337 tricalcium citrate Nutrition 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0918450.8A GB0918450D0 (en) | 2009-10-21 | 2009-10-21 | Composition |
| GB0918450.8 | 2009-10-21 | ||
| PCT/GB2010/001955 WO2011048379A2 (en) | 2009-10-21 | 2010-10-21 | Composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013508344A JP2013508344A (ja) | 2013-03-07 |
| JP2013508344A5 true JP2013508344A5 (enExample) | 2013-12-05 |
Family
ID=41426476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534763A Pending JP2013508344A (ja) | 2009-10-21 | 2010-10-21 | 組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130004542A1 (enExample) |
| EP (1) | EP2490670B1 (enExample) |
| JP (1) | JP2013508344A (enExample) |
| CN (1) | CN102665684A (enExample) |
| CA (1) | CA2777899C (enExample) |
| GB (1) | GB0918450D0 (enExample) |
| WO (1) | WO2011048379A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| MX354829B (es) | 2009-03-26 | 2018-03-22 | Pulmatrix Operating Co Inc | Formulaciones de polvo seco y metodos para el tratamiento de enfermedades pulmonares. |
| GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
| EP2464346A1 (en) | 2010-08-30 | 2012-06-20 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| CA2809666C (en) | 2010-08-30 | 2020-09-22 | Michael M. Lipp | Dry powder formulations and methods for treating pulmonary diseases |
| AU2011314007B2 (en) | 2010-09-29 | 2017-01-19 | Pulmatrix, Inc. | Cationic dry powders |
| RU2640921C2 (ru) | 2010-09-29 | 2018-01-12 | Пулмэтрикс, Инк. | Катионы одновалентных металлов сухих порошков для ингаляций |
| US20150165038A1 (en) * | 2012-02-10 | 2015-06-18 | Arven llac Sanayi Ve Ticaret A.S. | Compositions comprising muscarinic receptor antagonist and sorbitol |
| JP2015509788A (ja) | 2012-02-29 | 2015-04-02 | パルマトリックス，インコーポレイテッド | 吸入に適した乾燥粉末 |
| WO2014007772A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising glucose anhydrous |
| WO2014007769A1 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions comprising muscarinic receptor antagonist and glucose anhydrous |
| US10105316B2 (en) | 2012-07-05 | 2018-10-23 | Arven llac Sanayi Ve Ticaret A.S. | Inhalation compositions comprising muscarinic receptor antagonist |
| UA115989C2 (uk) * | 2012-07-05 | 2018-01-25 | Арвен Айлак Санайі Ве Тіджарет А.С. | Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії |
| WO2014074797A1 (en) * | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
| AU2013368298B2 (en) * | 2012-12-27 | 2016-08-11 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| CN104885172B (zh) * | 2012-12-27 | 2019-12-13 | 3M创新有限公司 | 电化学装置及其制造方法 |
| CA2907566C (en) | 2013-04-01 | 2023-08-22 | Pulmatrix, Inc. | Tiotropium dry powders |
| JP2015116367A (ja) * | 2013-12-19 | 2015-06-25 | 重人 下山 | 寝具装置、寝具装置制御方法及びプログラム |
| CN103830194A (zh) * | 2014-03-11 | 2014-06-04 | 熊妲妮 | 茚达特罗固体分散体及含有其的药物组合物 |
| AU2015338717B2 (en) | 2014-10-31 | 2018-12-20 | Glaxosmithkline Intellectual Property Development Limited | Powder formulation |
| WO2017100656A1 (en) * | 2015-12-11 | 2017-06-15 | Otitopic Inc. | Dry powder formulations of aspirin for inhalation |
| AU2019207288A1 (en) * | 2018-01-11 | 2020-08-13 | Emphysema Solutions Bv | Compositions and methods for the treatment of lung emphysema and other forms of COPD |
| GB201817861D0 (en) * | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Gel and crystalline powder |
| US20250049862A1 (en) * | 2021-12-16 | 2025-02-13 | Alveolus Bio, Inc. | Spray dried inhalable biotherapeutics for the treatment of disease |
| CN115046816B (zh) * | 2022-03-11 | 2025-09-26 | 桂林优利特医疗电子有限公司 | 一种尿液有形成分分析仪用结晶质控物的制备方法 |
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8802174D0 (en) | 1988-02-01 | 1988-03-02 | Quadrant Bioresources Ltd | Method of drying macromolecules |
| AU5414990A (en) | 1989-04-12 | 1990-11-05 | Aberdeen University | Slow release vitreous systems |
| GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
| EP0563455A1 (en) | 1992-03-31 | 1993-10-06 | Purac Biochem B.V. | Particulate solid products containing a lump forming inhibitor |
| EP0611567B1 (en) * | 1992-06-12 | 2002-08-28 | Teijin Limited | Ultrafine powder for inhalation and production thereof |
| ES2218543T3 (es) | 1994-03-07 | 2004-11-16 | Nektar Therapeutics | Procedimiento y preparacion para la administracion de insulina por via pulmonar. |
| JP3414539B2 (ja) * | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
| JP3095624B2 (ja) | 1994-07-19 | 2000-10-10 | 株式会社ボッシュオートモーティブシステム | 積層型熱交換器の偏平チューブのろう付け方法 |
| DE69531992T2 (de) | 1994-08-04 | 2004-07-22 | Elan Drug Delivery Ltd., Ruddington | Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung |
| GB9423419D0 (en) | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| JP4502406B2 (ja) | 1995-06-07 | 2010-07-14 | クアドラント、ドラッグ、デリバリー、リミテッド | 乾燥発泡ガラスマトリックス内に物質を安定に配合する方法及びそれによって得られた組成物 |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| GB9621825D0 (en) | 1996-10-19 | 1996-12-11 | Andaris Ltd | Microparticles and their use as therapeutic vehicles |
| AU2945199A (en) | 1998-03-18 | 1999-10-11 | Ronai, Peter | Amorphous glasses for stabilising sensitive products |
| DK1283036T3 (da) | 1998-11-13 | 2008-03-25 | Jagotec Ag | Törpulver til inhalation |
| PL196951B1 (pl) | 1999-03-05 | 2008-02-29 | Chiesi Farma Spa | Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika |
| UA75375C2 (en) | 2000-10-12 | 2006-04-17 | Boehringer Ingelheim Pharma | Method for producing powdery preparations for inhaling |
| DE10050995A1 (de) | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10050994A1 (de) | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung |
| US20020141946A1 (en) * | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
| DE10141376A1 (de) | 2001-08-23 | 2003-03-13 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Inhalationspulvern |
| DE10141377A1 (de) | 2001-08-23 | 2003-03-13 | Boehringer Ingelheim Pharma | Aufstreuverfahren zur Herstellung von Pulverformulierungen |
| JP2003062074A (ja) * | 2001-08-29 | 2003-03-04 | Tomohiko Hashiba | 吸入装置 |
| DE10203749A1 (de) | 2002-01-31 | 2003-08-14 | Boehringer Ingelheim Pharma | Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE10203753A1 (de) | 2002-01-31 | 2003-08-14 | Boehringer Ingelheim Pharma | Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE10203741A1 (de) | 2002-01-31 | 2003-08-14 | Boehringer Ingelheim Pharma | Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| EP1480996A1 (en) * | 2002-02-04 | 2004-12-01 | Glaxo Group Limited | Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form |
| WO2003079993A2 (en) | 2002-03-20 | 2003-10-02 | Advanced Inhalation Research, Inc. | hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION |
| WO2004060343A1 (en) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics | Antibody-containing particles and compositions |
| JP2005060330A (ja) * | 2003-08-18 | 2005-03-10 | Tomohiko Hashiba | 球状タンパク質粉体とその製造方法 |
| GB0520794D0 (en) | 2005-10-12 | 2005-11-23 | Innovata Biomed Ltd | Inhaler |
| MX354829B (es) * | 2009-03-26 | 2018-03-22 | Pulmatrix Operating Co Inc | Formulaciones de polvo seco y metodos para el tratamiento de enfermedades pulmonares. |
| AU2010229730A1 (en) * | 2009-03-26 | 2011-10-06 | Pulmatrix, Inc. | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining |
-
2009
- 2009-10-21 GB GBGB0918450.8A patent/GB0918450D0/en not_active Ceased
-
2010
- 2010-10-21 EP EP10781721.5A patent/EP2490670B1/en not_active Not-in-force
- 2010-10-21 WO PCT/GB2010/001955 patent/WO2011048379A2/en not_active Ceased
- 2010-10-21 JP JP2012534763A patent/JP2013508344A/ja active Pending
- 2010-10-21 CA CA2777899A patent/CA2777899C/en active Active
- 2010-10-21 US US13/501,303 patent/US20130004542A1/en not_active Abandoned
- 2010-10-21 CN CN2010800478259A patent/CN102665684A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2708218T3 (es) | Método y formulación para inhalación | |
| US20120083531A1 (en) | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining | |
| ES2837675T3 (es) | Un proceso para fabricar partículas de sílice porosa cargadas con al menos un compuesto bioactivo adaptadas para el suministro pulmonar, nasal, sublingual y/o faríngeo | |
| BR112013029803B1 (pt) | Composições de vancomicina em pó seco | |
| CN102665684A (zh) | 用于吸入的组合物 | |
| JP7277490B2 (ja) | 肺送達用ラパマイシン粉末 | |
| CN115701983A (zh) | 配制品 | |
| JP7629159B2 (ja) | 吸入用サーファクタント製剤 | |
| JP2003507411A5 (enExample) | ||
| US20250262150A1 (en) | Surfactant Formulations for Inhalation | |
| US20250288516A1 (en) | Surfactant Formulations for Inhalation | |
| WO2002045682A1 (en) | Particulate inhalation carrier | |
| ME02586B (me) | Unapređena suspendovana formulacija beklometazon dipropionata za administraciju putem inhalacije | |
| CA2630772A1 (en) | Respirable powders | |
| JP2025513460A (ja) | 粉末吸入による医薬品の送達 | |
| JP2018524346A (ja) | 肺送達のためのトリプタン粉末 |